[go: up one dir, main page]

Hu, 1997 - Google Patents

The effect of alpha-2-macroglobulin on dopamine concentration in corpus striatum andtrkB-mediated signal transduction and gene expression: A study on its potential …

Hu, 1997

Document ID
12324089228202094358
Author
Hu Y
Publication year

External Links

Snippet

Previous studies have shown that alpha-2-macroglobulin ($\alpha\sb2 $ M), once reacted with a monoamine, can adversely affect various neuronal functions, and $\alpha\sb2 $ M is associated with the pathogenesis of Alzheimer's disease. Our hypothesis is that once …
Continue reading at search.proquest.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Similar Documents

Publication Publication Date Title
Silhol et al. Age-related changes in brain-derived neurotrophic factor and tyrosine kinase receptor isoforms in the hippocampus and hypothalamus in male rats
Elkabes et al. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function
Columbano et al. Gadd45β is induced through a CAR‐dependent, TNF‐independent pathway in murine liver hyperplasia
Allsopp et al. Role of Bcl‐2 in the brain‐derived neurotrophic factor survival response
Zappala et al. Expression of pannexin1 in the CNS of adult mouse: cellular localization and effect of 4-aminopyridine-induced seizures
JP2007314575A (en) Prosaposin and cytokine-derived peptides as therapeutic agents
Arenas et al. Effects of BDNF and NT‐4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo
US20010052137A1 (en) Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
US6262024B1 (en) Neuron regulatory factor for promoting neuron survival
Gyárfás et al. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo
Prakash Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration
Waschbisch et al. Interleukin‐1 beta‐induced expression of the prostaglandin E2‐receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor‐kappaB
Knusel et al. Intraparenchymal NGF injections in adult and aged rats induce long-lasting Trk tyrosine phosphorylation
Polanski et al. The exceptional properties of 9‐methyl‐β‐carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti‐inflammatory effects
US11628206B2 (en) Method for inhibiting STAT3 activity comprising administering Ssu72
CN117836310A (en) Cell penetrating peptide, anticancer peptide and pharmaceutical composition comprising the same for preventing or treating cancer
Hu The effect of alpha-2-macroglobulin on dopamine concentration in corpus striatum andtrkB-mediated signal transduction and gene expression: A study on its potential role in neurodegeneration in the central nervous system
JP7630540B2 (en) Neuroprotective Peptides
EP1414478B1 (en) Inhibition of neurodegeneration
Nakazawa et al. Selective upregulation of RB3/stathmin4 by ciliary neurotrophic factor following optic nerve axotomy
PT101051A (en) USE OF ANTI-NT-3 NEUTRALIZING ANTIBODY AND RIBOZYME OR ANTI-SENSE MOLECULES IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND ANALYTICAL PROCESS RELATED TO NT-3
US20210002650A1 (en) Compositions and methods for treating alzheimer's disease
JPH08500836A (en) Treatment of cancer with neurotrophic factors and cell growth inhibitors
WO1998015628A1 (en) Novel semaphorin gene: semaphorin w
US7056667B2 (en) Spatial learning and memory